Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

SOFT LANDING LABS LTD

NPI: 1295967149 · HILLSIDE, IL 60162 · Clinical Medical Laboratory · NPI assigned 08/11/2009

$782K
Total Medicaid Paid
14,866
Total Claims
12,400
Beneficiaries
4
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialPATEL, RAJESH (VICE PRESIDENT)
NPI Enumeration Date08/11/2009

Related Entities

Other providers sharing the same authorized official: PATEL, RAJESH

ProviderCityStateTotal Paid
RAJESH C PATEL MD INC DAYTON OH $2.61M
INTERVENTIONAL PAIN MEDICINE PC HOLLIS NY $1.72M
RAJESH G PATEL MD PLLC JACKSON MS $614K
MAC ANESTHESIA, PC HOLLIS NY $145K
PSJ PHARMACY LLC COCOA FL $34K
FORRAYAN LLC PLAINFIELD NJ $24K
RAJESH J PATEL, M.D., P.A. ODESSA TX $17K
MAA BHAWANI INC BEVERLY HILLS FL $0.00
BREVARD PHARMACY LLC COCOA FL $0.00

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 1,542 $67K
2019 4,702 $180K
2020 2,732 $102K
2021 1,067 $71K
2022 1,229 $92K
2023 1,222 $85K
2024 2,372 $185K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 8,487 7,530 $349K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 2,835 2,389 $270K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1,100 746 $94K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2,444 1,735 $68K